Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PDE9A | O76083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12988802 | 0.78 | KDM4E (0.37) | KDM4EALDH1A1SMN1; SMN2GPR119RXFP1 | |
| SCHEMBL20009060 | 0.78 | HRH3 (0.43) | KDM4ESMN1; SMN2 | |
| SCHEMBL20009080 | 0.76 | KDM4E (0.39) | KDM4EGPR119RXFP1 | |
| SCHEMBL13035353 | 0.76 | KDM4E (0.39) | KDM4EGPR119RXFP1L3MBTL1LMNA | |
| SCHEMBL1713568 | 0.75 | KDM4E (0.38) | KDM4EALDH1A1SMN1; SMN2GPR119RXFP1 | |
| SCHEMBL20009051 | 0.74 | CHRNB2 (0.47) | — | |
| SCHEMBL20009032 | 0.73 | SLC6A7 (0.38) | KDM4EALDH1A1LMNA | |
| SCHEMBL20012694 | 0.73 | KDM4E (0.37) | KDM4EGPR119RXFP1 | |
| SCHEMBL20009007 | 0.73 | HRH3 (0.46) | GPR119GRM1 | |
| Hydrochloric Acid SCHEMBL19991677 | 0.72 | KDM4E (0.36) | KDM4EGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | KDM4E 1623/4885ALDH1A1 3032/4885SMN1; SMN2 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.